A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Melanoma|Cervical Carcinoma|Pancreatic Carcinoma|Triple Negative Breast Cancer|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced or Metastatic Solid Tumors|Prostate Carcinoma|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Intrahepatic Cholangiocarcinoma|Squamous Cell Anal Cancer|Squamous Cell Penile Carcinoma|Squamous Cell Vulvar Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma
Interventions: BIOLOGICAL: XmAb®22841|BIOLOGICAL: Pembrolizumab (Keytruda®)
Sponsor: Xencor, Inc.
Collaborators: ICON Clinical Research